Synaptic Ras GTPase Activating Protein (SYNGAP1): A Potential Drug Target and Biomarker

Target Name: SYNGAP1

NCBI ID: G8831

SYNGAP1

Synaptic Ras GTPase Activating Protein (SYNGAP1): A Potential Drug Target and Biomarker

Introduction

Synaptic ras GTPase activating protein (SYNGAP1) is a protein that plays a crucial role in synaptic plasticity, which is the ability of the nervous system to change and adapt over time. The SYNGAP1 gene was identified in 2004 and is located on chromosome 12q14. It is a 135kDa protein that is expressed in various tissues, including brain, heart, and muscle. The primary function of SYNGAP1 is to regulate the activity of the ras gene, which is a well-established gene involved in cell signaling.

SYNGAP1 functions as a GTPase activating protein (GAP), which means it can activate the GTPase activity of the ras gene. The ras gene is a key regulator of cell signaling pathways, including the cAMP/cGMP signaling pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and survival. The activity of the ras gene can be regulated by various factors, including SYNGAP1.

SYNGAP1 is a potential drug target because of its involvement in the cAMP/cGMP signaling pathway. Activating the ras gene via SYNGAP1 has been shown to enhance the activity of various cellular signaling pathways, including the cAMP/cGMP signaling pathway. This increased activity can lead to increased cellular signaling, which can contribute to the development of various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

SYNGAP1 is also a potential biomarker for several diseases. The ras gene is known to be involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The activity of SYNGAP1, as a GAP, can be regulated by various factors, including the ras gene. Therefore, changes in the activity of SYNGAP1 can be an indicator of the underlying health status of an individual.

Expression of SYNGAP1 and its potential clinical applications

SYNGAP1 is expressed in various tissues, including brain, heart, and muscle. It is a protein that can be detected using techniques such as Western blotting, immunofluorescence, and in situ hybridization. The expression of SYNGAP1 has been shown to be affected by various factors , including age, gender, and environmental conditions.

SYNGAP1 has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that high levels of SYNGAP1 expression are associated with poor prognosis in individuals with colorectal cancer. Additionally, SYNGAP1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential clinical applications, SYNGAP1 is also a potential drug target. The activity of SYNGAP1 can be regulated by various small molecules, including inhibitors of the ras gene. Therefore, inhibitors of SYNGAP1 have been shown to be effective in treating various diseases , including cancer, neurodegenerative diseases, and developmental disorders.

Conclusion

SYNGAP1 is a protein that plays a crucial role in synaptic plasticity and the cAMP/cGMP signaling pathway. It is a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. The activity of SYNGAP1 can be regulated by various small molecules, including inhibitors of the ras gene. Therefore, inhibiting SYNGAP1

Protein Name: Synaptic Ras GTPase Activating Protein 1

Functions: Major constituent of the PSD essential for postsynaptic signaling. Inhibitory regulator of the Ras-cAMP pathway. Member of the NMDAR signaling complex in excitatory synapses, it may play a role in NMDAR-dependent control of AMPAR potentiation, AMPAR membrane trafficking and synaptic plasticity. Regulates AMPAR-mediated miniature excitatory postsynaptic currents. Exhibits dual GTPase-activating specificity for Ras and Rap. May be involved in certain forms of brain injury, leading to long-term learning and memory deficits (By similarity)

The "SYNGAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYNGAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets